Market Overview

UPDATE: Credit Suisse Downgrades Mindray Medical International to Neutral, Lowers PT

Related MR
Mindray Announces Settlement of Previously Described Masimo Related Litigation
Benzinga's M&A Chatter for Wednesday November 4, 2015

In a report published Wednesday, Credit Suisse Group downgraded its rating on Mindray Medical International Ltd. (NYSE: MR) from Outperform to Neutral, and lowered its price target from $34.00 to $32.00.

Credit Suisse noted, “We learned from Mindray's management that there is potentially a major restructuring of Mindray's North America personnel. Combined with the negative impact of Mindray's voluntary recall and the FDA's warning letter issued on 19 November 2012 (which has not yet brought down Mindray's stock price meaningfully), this may lead to lower sales than consensus estimates...Our positive view on Mindray's long-term growth potential remains intact, but now, with Mindray's main near-to-medium term investment thesis switched from US sales ramp-up to IVD sales in China, we expect some investors to take profits after the 26% increase in 2012. We downgrade the stock to NEUTRAL and reduce our target price to US$32 based on 17x 2013E EPS.”

Mindray Medical International Ltd. closed on Monday at $33.01.

Latest Ratings for MR

Nov 2015Standpoint ResearchDowngradesBuyHold
Jun 2015JMP SecuritiesUpgradesUnderperformMarket Perform
Mar 2015JMP SecuritiesMaintainsMarket Underperform

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: Credit Suisse GroupAnalyst Color Downgrades Analyst Ratings


Related Articles (MR)

View Comments and Join the Discussion!

Partner Center